Organon Pharma Indonesia Tbk. vs WIR ASIA Tbk. — how do they compare? Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B), while WIR ASIA Tbk. trades at Rp77 (market cap 955.09B, 774.95M 24h volume). The key difference: WIR ASIA Tbk. is far larger — about 9.1× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| SCPI | WIRG | |
|---|---|---|
Market Cap | 104.4B | 955.09B |
Volume | — | 774.95M |
Lot | — | 7.75M |
Turnover | — | 61.67B |
Average Price | — | 79.57 |
Value | — | 61.67B |
Indicative Equilibrium Price | — | 77 |
Indicative Equilibrium Volume | — | 33.81K |
Trailing returns across standard periods
Latest headlines on both assets
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →PT WIR ASIA Tbk (the Company) was established on Notarial Deed No. 16 dated August 15, 2011 of Musa Muamarta, S.H. The Company started its commercial operations in 2013.
Read more on WIRG →